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INTRODUCTION
Isoniazid (INH, H) is a bactericidal first-line drug essential for 
the treatment of tuberculosis (TB).1 According to the World 
Health Organization (WHO), rifampicin (RFP, R)-susceptible, 
INH-resistant TB (INH mono-resistant TB, Hr-TB) accounts 
for approximately 8% of all TB cases worldwide.2 Although 
some previous studies3-7 have reported that resistance to INH is 
not associated with poor outcomes, several recent ones have 
suggested that patients diagnosed with Hr-TB have worse out-
comes than those with drug-susceptible TB3,8-11 when treated 
with first-line drugs only. Therefore, early detection and prop-
er management of Hr-TB are of paramount importance.
Currently, there are several diagnostic techniques for detect-
ing drug resistance, including the conventional drug-suscepti-
bility test (DST) and rapid molecular DST that detect specific 
DNA mutations in the genome of Mycobacterium tuberculo-
sis.12 The optimal use of currently available tests is important 
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for accurate diagnosis of Hr-TB, especially in high-TB-burden 
countries where diagnostic testing is limited, and further de-
velopment of more rapid and accurate testing techniques for 
detecting INH resistance would be desirable.
WHO guidelines,2 revised in 2018, recommend treatment 
with RFP, ethambutol (EMB, E), pyrazinamide (PZA, Z), and 
levofloxacin (LFX, Q) for a duration of 6 months in patients 
with Hr-TB. However, high-quality data in support thereof are 
lacking, and definitive guidelines on an optimal regimen and 
duration of treatment of Hr-TB have yet to be established. There-
fore, we evaluated the clinical characteristics of patients with Hr-
TB and explored their treatment outcomes over a 14-year period 
at a single center in South Korea. 
MATERIALS AND METHODS
Study population and data collection 
In this study, we retrospectively analyzed the records of pa-
tients diagnosed with culture-confirmed Hr-TB at a tertiary re-
ferral hospital in South Korea from January 2005 to December 
2018. Patient data were collected from electronic medical re-
cords and included demographic features, as well as results of 
laboratory, radiographic, and microbiological tests. Patients 
were considered to be immunocompromised if they were 1) he-
matopoietic cell transplant recipients, 2) other solid organ trans-
plant recipients, and/or 3) had received any immunosuppres-
sive treatments (e.g., biologic agents targeting inflammatory 
mediators or corticosteroid therapy).
Definition of Hr-TB and treatment outcomes 
We conceptualized Hr-TB as TB susceptible to RFP and resis-
tant to INH. An Hr-TB regimen was defined as a set of treat-
ment agents reserved for the second-line treatment of Hr-TB, 
following detection of Hr-TB by clinicians based on either con-
ventional or rapid molecular DST results. The principles of Hr-
TB treatment were based on WHO recommendations.13-15 When 
Hr-TB was confirmed without RFP resistance, clinicians con-
tinued the Hr-TB regimen with RFP, EMB, and PZA, and they 
also considered adding fluoroquinolone to the regimen. The 
regimens could be individually adjusted by the clinicians ac-
cording to disease severity, adverse events, and/or adherence 
to the treatment. Treatment extension was considered in the 
following cases: patients with cavitary forms, those who re-
mained smear-positive at the second month of treatment, those 
diagnosed with TB spondylitis, and those who were intolerant 
to first-line TB drugs.
Treatment outcomes were defined according to Korean TB16 
and WHO guidelines.17 A favorable outcome was defined as a 
cure and/or treatment completion without relapse, and an 
unfavorable outcome was defined as treatment failure, death 
during treatment, lost to follow-up, not evaluated, or relapse 
after completing the initial treatment.
Acid-fast bacillus (AFB) cultures and 
drug-susceptibility testing 
Sputum specimens were examined by fluorochrome staining 
using auramine–rhodamine and were cultured on both solid 
medium (3% egg-based Ogawa medium) and Mycobacteria 
growth-indicator tube medium (MGIT; Becton Dickson, NJ, 
USA, since 2008).
Conventional DSTs were conducted at the Korean Institute 
of Tuberculosis (KIT) until December 2016, after which it con-
tinued at Seoul Clinical Laboratories (SCL). DSTs were con-
ducted at KIT using the absolute concentration method with 
Lowenstein–Jensen medium and were performed at SCL us-
ing agar proportion methods with Middlebrook 7H10 medi-
um. Resistance to INH was classified into high-level [mini-
mum inhibitory concentration (MIC) ≥1.0 µg/mL] or low-level 
(MIC 0.1–1.0 µg/mL) resistance: high-level resistance to INH 
was defined as resistance to ≥1.0 µg/mL of INH. Low-level re-
sistance was defined as resistance to lower concentrations (0.1– 
1.0 µg/mL of INH), but susceptibility to higher concentrations 
(i.e., ≥1.0 µg/mL of INH). 
Rapid molecular DSTs were also performed using a line 
probe assay (AdvanSureTM MDR-TB GenoBlot Assay kit; LG 
Life Sciences Ltd., Seoul, Korea) to detect genetic mutations of 
M. tuberculosis.
Statistical analysis 
Categorical comparisons were analyzed using the Pearson’s 
chi-squared test or Fisher’s exact test. Continuous variables 
were compared using the Mann-Whitney test or t-test. Multi-
variate logistic regression analysis was used to identify risk 
factors associated with unfavorable outcomes. The odds ratios 
(ORs) and 95% confidence intervals (CIs) were also calculat-
ed. A p value<0.05 was considered significant for all analyses. 
Data analysis was performed using SPSS version 25 (IBM 
Corp., released 2017, Armonk, NY, USA).
Ethics statement
The study protocol was reviewed and approved by the Institu-
tional Review Board of Hospital (IRB No. 4-2020-0324), and 
the need for informed consent was waived by the committee.
RESULTS
Study population
From January 2005 to December 2018, 266 adult patients 
(aged ≥18 years) with culture-confirmed Hr-TB were enrolled. 
We excluded patients who were resistant to INH and one oth-
er first-line anti-TB drug (n=47), who were already under treat-
ment initiated at another hospital (n=10), who were not pre-
scribed medication at our hospital (n=12), and/or who were 
currently under treatment (n=4). Of the 266 patients, 71 were 





The baseline characteristics of the study population are shown 
in Table 1. The median age was 56.6 [interquartile rage (IQR), 
40.2–68.6] years, and 113 (57.9%) were male. Of the patients 
under study, 72 (36.9%) had a smoking history, and 54 (27.7%) 
had received prior TB treatment. AFB smear was positive in 61 
(31.3%) patients, and chest radiography detected cavitary le-
sions in 51 (26.2%). Phenotypic, high-level resistance was 
found in 138 (70.8%) patients, and low-level resistance was 
found in 57 (29.2%). Regarding treatment, 123 (63.1%) patients 
received a regimen of (H)REZ, accounting for the largest pro-
portion, followed by the (H)REZQ regimen. The durations of 
treatment were approximately 6 months in 67 (34.4%) patients, 
7–11 months in 95 (48.7%), and more than 12 months in 33 
(16.9%).
Comparative analysis of conventional and rapid 
molecular DSTs 
Table 2 shows the concordance between conventional and rap-
id molecular DSTs for the detection of INH resistance. Among 
all 195 Hr-TB patients, 145 (74.4%) had both conventional and 
rapid molecular DST results. Among the latter, 122 (62.6%) 
patients had specific genetic mutations conferring INH resis-
tance (Table 2A). Table 2B shows the mutation patterns of 
katG, inhA, and ahpC genes detected by rapid molecular DSTs. 
Mutations in katG were most frequent [54 (56.3%)], followed 
by inhA mutations [34 (35.4%)]. The katG mutations were all 
detected in patients exhibiting phenotypic, high-level INH re-
sistance. In contrast, inhA mutations were more frequent in pa-
tients with low-level resistance [27 (79.4%)]. 
Treatment outcomes
The clinical treatment outcomes are shown in Table 3. Of the 
195 Hr-TB patients, 168 (86.2%) achieved treatment success at 
the end of treatment, including cure [154 (79.0%)] and com-
pletion [14 (7.2%)]. The overall rate of favorable outcomes was 
84.1%. Unfavorable outcomes occurred in 31 (15.9%) patients: 
treatment failure [1 (0.5%)], death during treatment [5 (2.6%)], 
loss to follow-up [5 (2.6%)], not evaluated [16 (8.2%)], and re-
lapse after successful initial treatment [4 (2.1%)]. The duration 
from the end of treatment to diagnosis of relapse was 461.0 
days (IQR 124.3–1001.3). The characteristics of these relapsed 
patients are shown in Supplementary Table 1 (only online). 
Table 1. Baseline Characteristics
Variables Total (n=195)
Age (yr) 56.6 (40.2–68.6)
Sex, male 113 (57.9)
Body mass index, kg/m2 20.8 (19.2–23.1)
Underlying disease
Hypertension 56 (28.7)
Diabetes mellitus 39 (19.5)
Malignancy 35 (17.9)
Respiratory disease 31 (15.9)
Chronic kidney disease 11 (6.7)
Immunocompromised* 12 (6.2)
Smoking history 72 (36.9)





Baseline positive AFB smear 61 (31.3)
Cavitary lesions in chest radiography 51 (26.2)
Phenotypic DST
High-level resistance 138 (70.8)












6 months 67 (34.4)
7–11 months 95 (48.7)
12 months 33 (16.9)
TB, tuberculosis; AFB, acid-fast bacillus; DST, drug-susceptibility test; H, iso-
niazid; R, rifampicin; E, ethambutol; Z, pyrazinamide; Q, fluoroquinolone.
Data are presented as numbers (%) or medians (IQRs).
*Immunocompromised patients: 1) hematopoietic cell transplant recipients, 
2) other solid organ transplant recipients, and 3) patients who received any 
immunosuppressive treatments (e.g., biologic agents targeting inflammatory 
mediators, or corticosteroid therapy), †Others: includes multi-drug-resistant 
TB regimens, ‡Treatment duration: time from the initiation to the completion 
of TB treatment.
Hr-TB
from 2005.1.1 to 2018.12.31 (n=266)
Inclusion (n=195)
Exclusion (n=71)
• Resistance to INH and other first line drug (n=47)
- EMB (n=40)
- PZA (n=14)
• Started treatment at another hospital (n=10)
• Not prescribed medication at our hospital (n=12)
• Currently under treatment (n=4)
Fig. 1. Flow chart of the study population. Hr-TB, isoniazid mono-resistant 
tuberculosis; INH, isoniazid.
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Risk factors for unfavorable outcomes
To identify risk factors associated with unfavorable outcomes, 
we performed an analysis based on baseline characteristics, 
on-treatment culture status, and treatment regimens. Com-
pared to patients with favorable outcomes, those with unfavor-
Table 2. Conventional and Rapid Molecular DSTs for INH 









S   23 (11.8)
Not done   50 (25.6)
B. Phenotypic resistance according to specific mutations




High level (n=69) Low level (n=27)
katG 54 (56.3) 54 (100.0)   0
inhA 34 (35.4) 7 (20.6) 27 (79.4)
ahpC 2 (2.1)   2 (100.0)   0
katG & inhA 6 (6.3)   6 (100.0)   0
DST, drug-susceptibility test; INH, isoniazid; R, resistant; S, susceptible.
Data are presented as numbers (%). 
*Twenty-six patients did not have their mutation sites reported. 
Table 3. Clinical Treatment Outcomes
              Treatment outcomes Total (n=195)
Treatment success at end of treatment 168 (86.2)
Treatment failure 1 (0.5)
Death during treatment 5 (2.6)
Loss to follow up* 5 (2.6)
Not evaluated 16 (8.2)
Relapse 4 (2.1)
Primary study outcomes
Favorable outcomes† 164 (84.1)
Unfavorable outcomes‡ 31 (15.9)
Data are presented as numbers (%). 
*Loss to follow-up: treatment was interrupted for ≥2 months, †Favorable out-
comes: cure and/or treatment completion without relapse, ‡Unfavorable out-
comes: treatment failure, death, lost to follow-up, not evaluated, or relapse 
after completing the initial treatment.
Table 4. Univariate and Multivariate Logistic Regression Analyses for Unfavorable Outcomes
Variables
Unadjusted Adjusted
OR 95% CI p value OR 95% CI p value
Age (yr) 1.022 0.999–1.045 0.057 1.001 0.971–1.032 0.951
Sex, male 1.961 0.851–4.517 0.114 0.443 0.124–1.580 0.210
Body mass index, kg/m2 1.012 0.885–1.159 0.858 0.999 0.841–1.186 0.989
Hypertension 2.032 0.919–4.495 0.080
Diabetes mellitus 1.251 0.495–3.166 0.636
Malignancy 3.208 1.366–7.534 0.007 2.389 0.799–7.146 0.119
Respiratory disease 0.321 0.073–1.422 0.135
Chronic kidney disease 3.750 1.139–12.351 0.030 2.474 0.550–11.133 0.238
Immunocompromised* 1.845 0.470–7.242 0.380
Smoking history 4.653 2.044–10.590 <0.001 5.606 1.695–18.543 0.005
Prior history of TB treatment 1.835 0.822–4.096 0.139
Total protein level, g/dL 1.054 0.965–1.153 0.243
Albumin level, g/dL 0.220 0.117–0.415 <0.001 0.246 0.104–0.578 0.001
Baseline positive AFB smear 1.482 0.668–3.287 0.333
Cavitary lesions in chest radiography 1.722 0.755–3.928 0.196
High-level resistance 1.225 0.513–2.927 0.648
Fluoroquinolone use 0.847 0.374–1.920 0.692
Injectable agents use 0.464 0.058–3.727 0.470
Positive AFB culture at 1 month 2.226 0.845–5.861 0.105
Positive AFB culture at 2 months 7.692 1.938–30.532 0.004 7.853 1.246–49.506 0.028
Drug induced hepatitis 3.455 1.318–9.059 0.012 1.156 0.321–4.153 0.825
OR, odds ratio; CI, confidence interval; TB, tuberculosis; AFB, acid-fast bacillus.
*Immunocompromised patients: 1) hematopoietic cell transplant recipients, 2) other solid organ transplant recipients, and 3) patients who received any immuno-
suppressive treatments (e.g., biologic agents targeting inflammatory mediators or corticosteroid therapy).
able outcomes had greater frequencies of co-morbidity with 
malignancy (35.5% vs. 14.6%, p=0.010), chronic kidney disease 
(16.1% vs. 4.9%, p=0.037), and smoking history (67.7% vs. 
31.1%, p<0.001), as well as lower levels of protein (6.7 g/dL vs. 
7.1 g/dL, p=0.018) and albumin (3.2 g/dL vs. 4.0 g/dL, p<0.001) 
(Supplementary Table 2, only online). Positive AFB culture at 
2 months after treatment initiation (16.1% vs. 2.4%, p=0.006) 




Fig. 2. The age distribution of the study patients. (A) Histogram showing the age distribution of the study patients. (B) Box plot of the age distribution ac-
cording to treatment outcomes. (C) Box plot of the age distribution according to loss to follow-up or not evaluated. (D) Box plot of the age distribution ac-
cording to adverse events. d/t, due to; A/E, adverse events.
more frequent in patients with unfavorable outcomes than in 
those with favorable outcomes. Patients received Hr-TB treat-
ment for a median of 211.0 (IQR 124.0–273.0) days and treat-
ment as a whole for a median of 273.0 (IQR 187.0–342.0) days. 
Based on a multivariate analysis performed on baseline 
characteristics. as well as on-treatment culture status and regi-
mens, smoking history (OR=5.606, 95% CI: 1.695–18.543, p= 
0.005), low albumin level (OR=0.246, 95% CI: 0.104–0.578, p= 
0.001), and positive AFB culture at 2 months (OR=7.853, 95% 
CI: 1.246–49.506, p=0.028) were associated with unfavorable 
treatment outcomes (Table 4). 
Age distribution of the study patients
Fig. 2 shows the age distribution of the study patients. The me-
dian age was 56.6 (IQR, 40.2–68.6) years (Fig. 2A). There were 
no significant age differences between the unfavorable and fa-
vorable treatment outcome groups (62.0 years vs. 56.0 years, 
p=0.068) (Fig. 2B). However, we discovered that older age was 
associated with “loss to follow-up” or “not evaluated” as treat-
ment outcomes (p=0.039) (Fig. 2C). Furthermore, patients 
whose treatment regimens were altered or those who discon-
tinued treatment earlier than scheduled due to adverse events 
were older than those who maintained the same treatment reg-
imen (62.8 years vs. 54.6 years, p=0.041) (Fig. 2D). 
DISCUSSION
In this study, we evaluated the clinical characteristics and treat-
ment outcomes of patients with Hr-TB. The overall favorable 
outcome rate was 84.1%, which was not inferior o those report-
ed in recent meta-analyses of Hr-TB.9,11,18 The favorable treat-
ment outcome rate in the current study was also higher than that 
in patients with multidrug-resistant TB (76.6%) from 2005–2017 
at our institution.19 The results for Hr-TB were, however, inferior 
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covered that several factors were associated with unfavorable 
outcomes, including smoking, low level of albumin at diagno-
sis, and positive culture at 2 months of treatment.
One of the explanations for the relatively poor treatment out-
comes in our study might be the older age of the participants. 
They had a median age of 56.6 (IQR 40.2–68.6), which was high-
er than that of patients from the aforementioned studies,19-21 
possibly leading to suppressed treatment success. Treatment 
outcomes in older adult patients are known to be worse than 
those in their younger counterparts, mainly because of de-
layed diagnosis, frequent co-morbidities, and increased rates 
of adverse events.22 Among our participants, patients whose 
treatment regimens were altered or those who discontinued 
treatment earlier than scheduled due to adverse events were 
older than those who maintained the same treatment regi-
men. We further discovered that older age was associated with 
loss to follow-up or not undergoing evaluation, which were 
major forms of unfavorable outcomes in the current study. 
Thus, to improve the treatment outcomes for Hr-TB, regular 
monitoring, supportive intervention to maintain strict adher-
ence to the recommended TB treatment, and effective man-
agement of adverse reactions are needed for older patients.
The WHO guidelines, revised in 2018, suggested that treat-
ment success rate was higher when fluoroquinolone was add-
ed to the (H)REZ regimens;2 thus, they recommended Hr-TB 
treatment with RFP, EMB, PZA, and LFX for 6 months. How-
ever, in our study, we did not find significant differences in fa-
vorable outcomes between patients receiving fluoroquinolones 
and those who did not. In this study, only 36.3% of patients re-
ceived fluoroquinolones as a therapeutic agent, probably be-
cause this study utilized data from as far back as 2005, before 
the guidelines were revised. Thus, fluoroquinolones might 
have been administered to patients who had extensive disease 
or experienced adverse drug reactions. It was not possible to 
control for all the possible confounding in this study. 
For the diagnosis and treatment of Hr-TB, an empirical ap-
proach is generally not advised.23 Thus, rapid detection of Hr-
TB with laboratory confirmation plays an important role in 
accurate treatment. However, a conventional DST is time con-
suming; therefore, Hr-TB may be undetected and mistaken for 
pan-susceptible TB, which may lead to insufficient treatment 
and the spread of Hr-TB.9 In addition, conventional DSTs may 
yet be unavailable in resource-limited, high-TB-burden coun-
tries.24 Although line probe assay is also used as a rapid molec-
ular test to identify INH and RFP resistance through gene mu-
tations,25 the sensitivity of INH resistance detection by this 
method is lower than that of RFP resistance detection.26 The 
sensitivity of rapid molecular DSTs in the current study was 
84.1%, a finding consistent with the results of a meta-analysis.27 
As other genetic mutations associated with INH resistance 
have yet to be discovered, further development of rapid and 
accurate testing techniques for the detection of INH resistance 
is needed. To this end, the use of whole-genome sequencing, 
which uses the complete DNA sequence of an organism’s ge-
nome,28 may prove beneficial: according to findings from a pro-
spective study,29 whole-genome sequencing predicted drug-
susceptibility with an accuracy of 93%.
In our data, more than half of the attending physicians al-
tered the treatment regimen for Hr-TB after obtaining results 
from full phenotypic DSTs, including PZA and LFX. This took 
over 1 month, which is longer than the turn-around time of a 
rapid molecular test for INH. The exclusion of RFP resistance 
is essential before commencing Hr-TB treatment, and exclu-
sion of resistance to fluoroquinolones and PZA before Hr-TB 
treatment with a fluoroquinolone-containing regimen is ideal 
to reduce the acquisition of additional drug resistance.23
Updated WHO guidelines recommended, as a minimum, 
rapid molecular testing for RFP resistance before commenc-
ing treatment with an Hr-TB regimen. However, we found 47 
patients (among 266 INH resistance-confirmed patients) with 
resistance to INH and EMB or PZA simultaneously during the 
study period, though we excluded them from the final study 
population. We also discovered eight cases of Hr-TB isolates 
resistant to fluoroquinolone (among 266 INH resistance-con-
firmed patients). Even though drug-resistant TB surveillance 
has indicated that fluoroquinolone resistance among RFP-sus-
ceptible TB patients is generally low,30 reliable and rapid mo-
lecular methods for the exclusion of fluoroquinolone and PZA 
(possibly) before administering a Hr-TB regimen are urgently 
necessary.
There were a few limitations to our study. First, we did not 
compare Hr-TB to drug-susceptible TB. Second, our study was 
a single-center trial, and the results may not be applicable in 
other settings. The retrospective design of this study was limited 
to the review of medical records; therefore, our data may not be 
as accurate as data collected within the context of a prospec-
tive study. Third, since pre-revised guidelines recommended 
the addition of fluoroquinolone only for extensive disease bur-
den, fewer cases involving its administration were reported in 
this study, which includes data from 2005. Due to the small 
sample size, analysis of the association between treatment reg-
imens and treatment outcomes was limited. Fourth, our data 
includes 16 cases of patients with “not evaluated” outcomes, 
including 14 cases of domestic transfer out, and two cases of 
international transfer out. Although the final treatment out-
come for patients with “not evaluated” outcomes is unknown, 
this study classified these cases as unfavorable outcomes. It is 
important to systematically operate national databases to en-
sure that the treatment of transferred-out patients is consistent 
and complete.
In conclusion, 84% of Hr-TB patients achieved favorable out-
comes with guideline-based treatment, and previous smoking 
history, low levels of albumin, positive AFB culture at 2 months 
of treatment, and development of drug-induced hepatitis dur-
ing treatment were associated with unfavorable treatment out-




is required to improve treatment outcomes. Furthermore, 
though the line probe assay helps in the detection of Hr-TB, 
further research into more rapid and accurate techniques for 
detecting resistance to INH and other Hr-TB treatment drugs 
is warranted.
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